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of Asthma
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Abstract
Asthma is a chronic respiratory disease whose prevalence is increasing in the western world. Recently research
has begun to focus on the role the microbiome plays in asthma pathogenesis in the hope of further understanding
this respiratory disorder. Considered sterile until recently, the lungs have revealed themselves to contain a unique
microbiota. A shift towards molecular methods for the quantification and sequencing of microbial DNA has
revealed that the airways harbour a unique microbiota with apparent, reproducible differences present between
healthy and diseased lungs. There is a hope that in classifying the microbial load of the asthmatic airway an insight
may be afforded as to the possible role pulmonary microbes may have in propagating an asthmatic airway response.
This could potentially pave the way for new therapeutic strategies for the treatment of chronic lung conditions
such as asthma.
Keywords: Asthma, Host, Microbe dialogue, Translational research, Medicine, Inflammation, Microbiology,
Epithelium, Hygiene hypothesis
Background
Asthma has seen a staggering rise in prevalence in re-
cent years with more than 300 million people worldwide
believed to be affected by this chronic respiratory
disorder [1–3]. The burden of asthma is felt globally,
however it is in developed countries that asthma has
come to the fore as a health care concern [4] where the
incidence rate of asthma and in particular adult onset
asthma has risen so dramatically that this respiratory
disorder has reached epidemic proportions [5]. The inci-
dence of childhood asthma in the Western world has
also reached worrying levels [6]. Recently research has
begun to focus on the role microbes play in this chronic
respiratory disorder. Thanks to advances in sequencing
technologies it is now possible to dissect the role micro-
bial composition and diversity can play in a multi-factorial
disorder such as asthma. It is beginning to become clear
that there are clear differences present between asthmatics
and non-asthmatics and the microbial load they carry.
Through gaining an insight into the unique microbiota of
asthmatics much may be revealed, as has happened in
gastrointestinal microbial research, which could undoubt-
edly aid in disease prognosis and treatment.
Microbes and the airway
While research into respiratory diseases has rewarded us
with pharmacological treatments such as inhaled corti-
costeroids, leukotriene receptor antagonists, β agonists
and more recently targeted monoclonal therapies which
have helped alleviate the burden of asthma it is only
since ca. 2010 that research has confirmed that the en-
vironment of the lungs are not sterile as had previously
been believed [7, 8]. Prior to this the prevailing dogma
was that if bacteria were detected in the lower respira-
tory tract it was understood to represent an abnormal
health state and that the healthy lung was sterile [9].
This belief arose mainly due to poor, ineffective mi-
crobial culturing techniques which were unable to
replicate the lung habitat and culture the microbes
from respiratory specimens [10]. However it is clear
that although the lung contains a smaller bacterial
burden than in the upper respiratory tract there is a
distinct microbiota present in the lower airways of
healthy individuals [11]. This finding that the lungs
harbour a unique microbiota irrespective of health or
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disease has led to the surge of research now taking
place in an effort to not only categorise the distinct
microbiota of the diseased lung but also that of the
healthy lung [12]. Thanks to the advancement of cul-
ture independent techniques the unique steady state
microbiota of the lungs is being elucidated [9]. A
change in the microbial composition of the lower air-
way microbiota may be connected with chronic lung
disease such as asthma [2, 13].
The development of inexpensive next generation se-
quencing techniques, developed for the Human Genome
Project to sequence the human genome, has made it pos-
sible to determine microbial, in particular bacterial, com-
munities in a culture independent manner. By screening
the diversity of bacterial ribosomal rRNA genes present in
biological nucleic acid samples against sequence databases
and development of bioinformatic algorithms have en-
abled the organisation and interpretation of the huge data
sets made available by these sequencing machines [14, 15].
Meta-genomic approaches have enabled a far greater un-
derstanding of the microbes present at various sites and
the role they play in the overall host-microbiome inter-
action [15]. Thanks to culture independent techniques
low levels of oral bacteria such as Prevotella and Veillo-
nella have been discovered in the lower airways of healthy
individuals [15–17].
Lung environment
With a surface area of 75 m2 and direct exposure to the
environment, the lungs are prime sites for microbial ex-
posure [10]. As the environmental conditions shape the
composition of the microbial communities in that habi-
tat it is important to understand the environment of the
lungs to fully understand the potential microbes which
could inhabit this location, see Fig. 1. The lungs cannot
be viewed as one standard habitat, as they in fact consist
of microenvironments in which differences in temperature,
pH, mucus production, epithelial specialisation, the motil-
ity of the mucociliary escalator, oxygen concentration and
nutrient availability all have the potential to influence the
variety and type of microorganism present [18, 19]. Such
physiochemical property gradients may plausibly allow for
the survival of different microorganisms within varying
regions of the airways. It should be noted however that a
recent study has concluded that in the lungs of healthy in-
dividuals spatial variation in the microbiota appears to be
far less significant than the variation present across indi-
viduals [20]. The authors also reported that the microbiota
of the lung in health seems to be more influenced by the
immigration and elimination of microbes rather than by
the growth conditions influencing bacterial growth rates.
Furthermore, this pattern may be reversed in patients with
advanced lung disease due to alterations in the pulmonary
environment induced by disease progression [20]. As the
lungs are connected directly to the microbial rich oral and
nasal passages, the potential for regular translocation of
microbes from these sites secondary to inspiration and
with possible associated micro aspiration, it is therefore
not surprising that there may be similarities between the
microbial composition of these sites. To investigate this
further, Venkataraman et al., utilised a neutral model for
community ecology to differentiate members of the lung
microbiome whose presence in the lungs is consistent with
dispersal from other body sites and the members of the
lung microbiome who deviate from this model, suggesting
a competitive advantage for these microbes in the lung
[21]. From this study dispersal of microbes from the oral
cavity would seem to be the main mechanism whereby the
lungs become colonised in healthy individuals and as no
species constantly deviated from the neutral model one
might postulate that it is the constant dispersal that is
important for the microbial structure of the lower lungs
rather than selective pressure [21]. However, the process
could possibly be more complex than suggested in this
neutral model, with the possibility that microbes intro-
duced into the airways are killed at the same rate in which
they are introduced, creating a homeostatic balance and
therefore the perception of a neutral distribution, when in
fact the lung environment is highly selective.
Sample collection and the lungs
Due to the belief that the lungs were sterile and due to
the invasive nature of bronchoscope sampling the lower
respiratory tract was not, at first, included in the Human
Microbiome Project [22]. As recent characterisation of
the lung microbiota has revealed, there are definable
reproducible differences between healthy and diseased
state lungs. It is now accepted that the healthy lung
microbiome is diverse and some studies have even shown
that the respiratory tract can more rapidly acquire diver-
sity after birth than the intestines [23]. While there is now
acceptance that there are microbes present within the
airway, the challenge remains in overcoming the difficulty
in sampling and culturing these microbes from the lower
respiratory tract. The validity of sampling techniques such
as bronchoalveolar lavage (BAL) fluid and bronchial
brushes have been subject to debate due to the potential
for contamination from the oropharynx during bronchos-
copy. Despite such concerns, recent studies have shown
that, by comparing the microbial species present in the
upper respiratory tract with the microbiota of the lower
respiratory tract, the microbiota within the lower respira-
tory tract are unique. A recent study by Bassis et al., com-
pared samples from healthy subjects collected by oral
wash, BAL fluid, nasal swab and gastric aspirates and
demonstrated that the oral microbiome did not contamin-
ate BAL samples [22]. The oral cavity and stomach con-
tained high species richness and the highest bacterial
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signal levels in comparison to both the nasal cavity and
lungs which had much lower bacterial signal levels. Whilst
it was seen that the bacterial communities present in the
healthy lung overlapped with those present in the oro-
pharynx, the concentrations were much lower in the lungs
and there was a different community composition in
samples from healthy lungs [22].
While the sampling technique is of concern with regards
to contamination, caution should also be taken with sample
processing and the generation and analysis of complex
datasets. Unintentional environmental contamination when
processing can lead to the unintentional identification of
contaminants by the powerful sequencing technologies
and controlling potential sources of contamination such
Fig. 1 Factors influencing the lung microbiome. Schematic illustrating the complex factors affecting the lung microbiome in Asthma. The lung
microenvironment selects for specific microbes which change in Asthma due to environmental factors, infection and treatment options which
modulate the inflammatory cascade at the epithelial interface and the corresponding microbiome. Asthmatics display a changed
microbiome with increased lung microbes such as Haemophilus, Neisseria, Moraxella, Staphylococcus, and Streptoccoccus with reduced
Veillonella, Faecalibacterium, Lachospira and Rothia sp
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as reagents is vital. It is also important to avoid bias
and extraction protocols are critical. In sequencing of
samples it is usually one of the variable regions of the
16S rRNA gene that is targeted by primers, however
this is not ideal for the detection of certain species such
as fungi where 18S rRNA and internal transcribed spa-
cer sequencing represent a more appropriate target and
viral identification requires approaches other than
marker-gene-directed PCR analysis [24].
Lung diseases
The effect of the lung microbiome composition on
health and disease states is of interest not just in asthma
research but for other respiratory diseases such as cystic
fibrosis (CF), COPD, pulmonary fibrosis, and bronchiec-
tasis. In bronchiectasis it is now believed that a change
in composition of the lung microbiota through events
such as antibiotic therapy and inflammation may have
downstream consequences for the function of the im-
mune system, allowing for the formation and preserva-
tion of chronic infection lead by microbial pathogens
[25]. There is an appreciation that cystic fibrosis is a
multisystem disease with involvement of the hepatobili-
ary and gastrointestinal tracts [26]. While gastro-
oesophageal reflux (GOR) effects CF patients, the lung
and gastric microbiomes and an inter-dependant rela-
tionship between the two is clearly defined. Gastric and
sputum cultures have revealed that 73% of patients with
CF had one or more microorganism (fungal or bacterial)
in common between the two samples and among the
bacteria found in the two sites were Pseudomonas,
Streptococcus and Achromobacter. Pseudomonas aerugi-
nosa (Pa), a bacteria typically associated with CF was
found in the sputum samples of 11 patients of which 4
had identical Pa isolates in the stomach. In comparison,
non CF gastric juice samples revealed a higher diversity.
The stomach microbiome in patients with CF may act as
a potential pathogen reservoir and the aerodigestive
microbiome warrants further research as it may impinge
on the pathophysiology of CF [27]. Bile acid aspiration is
a comorbidity factor linked to many lung diseases which
could plausibly shape the lung microbiome and promote
the colonisation of Pa in CF patients. Using a systems
based analysis involving transcriptomics, functional gen-
omics and immunochemistry the network of genes in-
volved in virulence, adaptive metabolism and antibiotic
tolerance linked to the bile response of the pathogens
and the host cells has been eludicated. Bile acid leakage
into the oesophageal tract occurs in up to 80% of CF pa-
tients and occurs in up to 35% of COPD patients (al-
though this figure is thought to be underestimated) [28].
Disease progression and antibiotic tolerance in respira-
tory patients may be linked to bile acid signalling. Bile
acids can elict biofilm behaviour in Pseudomonas
aeruginosa, increase polymyxin and macrolide antibiotic
tolerance, and reduce microbial biodiversity [28]. COPD
research is in its infancy with regards to the microbiota
of the COPD lung however some recent studies have
demonstrated that as the disease progresses there is a
reduction in bacterial diversity however there is no
demonstratable outgrowth of a single microorganism
as is the case in CF where Pseudomonas aeruginosa
predominates [29]. Patients with idiopathic pulmonary
fibrosis (IPF) are reported to have a higher relative
abundance of Haemophilus, Streptococcus, Neisseria
and Veillonella species [30].
Asthma characteristics
Asthma is a chronic inflammatory disease, which is
characterised by airway hyper-responsiveness leading to
intermittent, repeated bouts of wheezing, chest tight-
ness, breathlessness and coughing [31, 32]. Asthma has
a complex heterogeneity with many clinical phenotypes
whose varying expression depends on interplay between
numerous environmental factors along with many differ-
ent susceptibility genes [1, 33]. The airway epithelium is
pivotal in the inflammatory response of the host and is a
major source of proinflammatory mediators [33]. TH2
cells subsequently play a prominent role in allergic dis-
order pathogenesis leading to B cells isotype switching,
generating IgE antibodies which are specific to the par-
ticular insulting allergen [8]. TH2 cells further enlist and
enhance survival of eosinophils and mast cells, induce
goblet cell hyperplasia and further drive bronchial hyper
reactivity [31]. The airway obstruction which charac-
terises the clinical presentation of asthma runs in cycles
of symptom free periods followed by varying periods of
exacerbation to which there is usually a trigger or stim-
uli [34]. These exacerbations result in a worsening in
symptoms and lung function and although is generally
reversible and followed by a return to normal lung func-
tion, in some patients repeated exacerbations may lead
to a new, compromised baseline [35, 36]. Such exacer-
bating triggers include infection, aeroallergens, pollution,
drugs and physical stimuli [31, 37, 38]. These exacerba-
tions are often treated with varying combinations of in-
creased inhaled therapy, systemic corticosteroids and
antibiotics [8]. One might postulate, therefore, that the
exacerbating event and the mode of therapy utilised to
treat the event may impact on the composition of the
lung microbiome. Indeed recent studies have demon-
strated that the gut microbiota can alter circadian
rhythms which may open new avenues of research into
identifying the cause of asthmatic exacerbations [39, 40].
It has been noted that an alteration to the Bmal 1 (the
clock gene) in bronchiolar cells disrupts the circadian
neutrophil recruitment via CXCL5, which in turn leads
to an exaggerated host response to LPS (lipopolysaccharide)
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and a deficient host immune response to Streptococcus
pneumoniae [41].
Epithelial development and the role of the microbiota
In the gastrointestinal tract there is a complex interplay
between the symbiotic bacteria which are responsible for
processes such as nutrient metabolism and the host
which in turn provides a nutrient rich, protective envir-
onment. This interplay requires strict sequestration of
the resident microbes and the host lumen to prevent the
triggering of processes such as sepsis and inflammation.
Epithelial antimicrobial proteins play a vital role in hin-
dering the contact of resident microbes and the host
mucosal surfaces. Germ-free mice and antibiotic treat-
ment of murine models have demonstrated evidence
that the microbiota is required for gut epithelia develop-
ment and function. Cash et al., first identified the role
microbes play in inducing antimicrobial peptides and
epithelial villus development and maturation [42]. It has
been seen that in germ-free mice microbial colonisation
induces the expression of RegIIIγ which is a secreted C-
type lectin, known in humans as HIP/PAP. This expres-
sion directly correlates with bacterial expression and
host epithelial contact, with preferential binding to pep-
tidoglycan which is present in gram positive bacteria.
This highlights how the host-microbial symbiotic rela-
tionship is maintained [42]. It is therefore possible that a
similar protective mechanism could be involved in the
lung mucosal epithelium.
Innate Lymphoid Cells (ILCs) have emerged as a
population of innate immune cells derived from an Id2
dependent lymphoid cell progenitor cell population.
ILCs share many functional and developmental charac-
teristics with CD4+T cell populations. ILCs have been
demonstrated to be involved in orchestrating certain
host-commensal bacteria relationships [43]. Such an in-
volvement would have implications on immunity, in-
flammation and tissue homeostasis in the intestines. In
the lungs it has been seen that pathogenic ILC responses
have been associated with asthma and airway hyperre-
sponsiveness in murine models [43]. As commensal bac-
teria, epithelial cells and ILCs share close proximity and
investigation into the potential impact of this interaction
upon the development of ILCs is taking place. Hence
ILCs may represent a potential target for numerous
human diseases such as asthma [43].
Recent studies focusing on ILCs have also identified
the key dialogue between ILCs, epithelia and the micro-
biota. IgA is the predominant antibody at mucosal sur-
faces, in particular in the upper respiratory tract.
Through its pleiotropic effects IgA induces a tolerizing
phenotype at mucosal surfaces and is of critical import-
ance to the maintenance of mucosal homeostasis. IgA is
created through the class switch recombination of Ig
heavy chains. IgA offers an important role in mucosal
homeostasis such as opsonisation and neutralisation of
pathogens and toxins. This results in a reduction of anti-
genic load on the mucosal immune system. In IgA−/−
mice the protective role of IgA at mucosal surfaces is
highlighted as these mice have an impaired clearance of
luminal pathogens such as Mycobacterium tuberculosis,
Streptococcus pneumoniae, Citrobacter rodentium, Giar-
dia muris and Giardia lamblia [44]. It has been demon-
strated that the microbiota acts through Toll-like
receptors to condition lung dendritic cells (LDCs) to
produce TGF-β and this in turn influences the produc-
tion of IgA in the lung [44]. While research to date has
focused mainly on the gut, evidence of bi-directional
links between the gut and the lung immune function are
increasing [45].
Microbes and the host
A key feature of any microorganism is its ability to be
recognised and sampled by the immune system. The en-
suing immune response, depending on the microbe, can
range from benign tolerance to acute inflammation and
injury, with ensuing repair and remodelling in the lungs
[3]. Respiratory fungi, bacteria and viruses are recog-
nised by innate receptors including Toll-like receptors
(TLRs), RIG-1-like helicases and NOD-like receptors
which when stimulated then activate the nuclear factor κ
B (NFκB) group transcription factors with the possible
resultant induction of more than 100 pro-inflammatory
and host response genes [3, 46]. Microorganisms can
affect the permeability of the epithelium increasing in-
fection risk, affecting epithelial integrity by invasion of
the epithelium cells leading to cell death and shedding.
By compromising the epithelium, subsequent allergen
uptake and the effect of environmental exposure to
pollutants may cause an increased possibility for the
development of further exacerbations and a heightened
immune response increasing the risk of a pathogenic
response and asthma development [3, 47–49].
Asthma patients have an increased risk of bacterial in-
fection and through culture dependent and independent
techniques it has been seen that there is increased car-
riage of pathogenic respiratory bacteria. Birth cohort
studies have shown that increased carriage of bacteria
such as Streptococcus pneumoniae, Haemophilus influen-
zae and Moraxella catarrhalis in early life can be linked
to asthma risk and the development of recurrent wheeze
in children born to asthmatic mothers [50]. This study
by Bisgaard et al., also revealed that, in children with re-
current wheeze during the first 3 years of life, that these
wheezing episodes are associated with bacterial and viral
infections equally, suggesting that bacterial and viral in-
fections may act independently to contribute to asthma
symptoms and thereby highlighting the important role
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of bacterial infection independent of viral infection in
the pathogenesis of asthma [51]. In a study by Hilty
et al., members of the phylum Proteobacteria were as-
sociated with airway disease in both asthma and COPD
patients. Haemophilus, Moraxella and Neisseria spp.
found in the lungs of asthmatic patients had strong cor-
relations with increased asthma risk when found in the
oropharynx of neonates. Staphylococcus was found to
be present in the airways of children with difficult
asthma. Bacteroidetes and in particular Prevotella and
Veillonella spp. were found to be most prevalent in
healthy controls [2].
While microorganisms can add to the onset and pro-
gression of atopic asthma, microorganisms can also have
a protective function [3]. The ‘hygiene hypothesis’ can in
part help to explain the disproportionate spread of
asthma in the western, industrialised world. It proposed
that repeated exposure to diverse common infections
and repeated exposure to environmental microbes dur-
ing childhood can stimulate the immune system in a
manner which promotes a protective responseagainst
future asthma risk [3].
The so-called ‘hygiene hypothesis’ contends that ex-
posure to soil, dust, microbes, antibiotics, vaccinations,
farm animals and family size in addition to factors such
as caesarean section birth versus vaginal birth and exclu-
sive formula feeding versus breastfeeding can all in some
part determine asthma risk [52–54]. In one meta-analysis
study there was a 20% increase in the subsequent risk
of asthma development in children born by caesarean
section [55].
The use of anti-inflammatory drugs and antibiotics
can significantly alter the lung microbiome [56]. Such a
change in the microbiome of the lung may lead to resist-
ance, resilience, functional redundancy, or a permanently
altered microbiome [11]. It is seen that even before
birth children are exposed to antibiotics, with about
half of all pregnant women in America receiving anti-
biotics which alter their microbiota before transfer to
their offspring [11].
Environmental microbial exposure can have a protect-
ive effect against asthma development. In the PARSIFAL
and GABRIELA studies asthma and atopy prevalence
among children living on farms and among children in
the reference group (not living on a farm) were exam-
ined. In both studies children living on a farm had a
lower prevalence of asthma than the reference group
From these two large scale observational studies it would
appear that a wider range of microbial exposures offers a
protective effect on the development of asthma [57].
It has been shown that single nucleotide polymor-
phisms (SNPs) in TNFAIP3 which encodes A20 is linked
to the development of asthma in farm dwelling children.
A20 is an ubiquitin-modifying enzyme which weakens
NFκB activation through the deubiquitination of key
signalling intermediates down-stream of IL-1 receptor,
Toll-like receptor and TNF family receptors. It is accepted
that chronic exposure to low-dose endotoxin or farm dust
conveys a protective effect against the development of
house dust mite (HDM) induced asthma in mice and loss
of A20 is associated with allergy and asthma risk. It has
been shown that in mice with an induced absence of A20
there is an increased sensitivity to HDM and the ensuing
asthma is seen to be more severe [58].
Children from rural areas in Germany, Austria and
Switzerland from farming and non-farming households
were involved in a study to determine whether there was
a protective effect present upon endotoxin exposure
against the risk of asthma and atopic wheeze. Mattress
dust, as an indicator for endotoxin exposure, was exam-
ined and it was found that environmental exposure to
endotoxins was associated with the development of
tolerance towards ubiquitous allergens found in natural
environments [59]. Muramic acid, a component of bac-
terial peptidoglycan, is a marker for microbial burden
and is a biologically active substance which influences
the cellular immune response in a manner different to
endotoxin. A high level of muramic acid in a similarly
constructed study provided complimentary findings,
lending further credence to the notion that asthma could
in part be due to inadequate activation, at the appropri-
ate educational time point, of the innate immune re-
sponses which are stimulated by certain microbial
products [60].
Recent studies, including the Canadian CHILD cohort
study, have highlighted the importance of this window
of colonisation in children and long-term side effects
such as asthma which can ensue when there is a pres-
ence or lack of certain microorganisms in the gastro-
intestinal system. It was determined that the relative
abundance of the bacterial genera Faecalibacterium,
Lachnospira, Veillonella, and Rothia (FLVR) appeared
notably decreased in the gut of children who were at risk
of developing asthma [61]. These microorganisms ap-
peared to be mostly significantly different between the
groups at 3 months and this difference decreased once
the children reached 1 year of age, suggesting the pres-
ence of a colonisation “window of opportunity” [61, 62].
It was also seen that it is not just the prevalence of the
gut microbiota that is important but the metabolites that
they derive, such as the short chain fatty acids (SCFAs)
propionate and acetate which have been demonstrated
in a murine model to reduce airway cellular infiltration
[61, 63]. This concept of a “window of opportunity” for
colonisation, while now generally accepted, requires fur-
ther investigation. In mice this critical window occurs
during the first 2–3 weeks of life and it is expected that
in humans the critical window is narrower than first
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expected and rather than years is likely to merely last for
a matter of months [62].
In germ-free mice it has been shown by Olszak et al.,
that there is dysregulation in the development of an im-
mune cell profile when there has been no microbial ex-
posure. However if colonised gastrointestinally during a
crucial neonatal period with a microbiome, a protective ef-
fect against exaggerated inflammation developed and this
effect could not be demonstrated in recolonised adult
mice [64]. Hence, one might postulate that if microbial ex-
posure can alleviate or prevent the immune cascade as
seen with allergic disorders such as asthma, could a pre-
biotic or probiotic have a protective or even preventive
role in asthma? It has been seen that Lactobacillus reuteri,
when administered to mice demonstrating a normal mi-
crobial flora, can abate airway hyperresponsiveness via
systemic increase in regulatory T cells, which can there-
fore alleviate asthma symptoms [65–67]. It was seen also
that direct exposure to an innocuous strain of Escherichia
coli could result in long term protection against allergic
disorders in normal mice by reprogramming macrophages
and dendritic cells [68]. Dendritic cells bridge the gap be-
tween innate and adaptive immunity [52]. In BALB/c ov-
albumin challenged mice fed daily with Bifidobacterium
longum it was noted that airway inflammation was attenu-
ated and a reduction in BAL eosinophilia, BAL fluid IL-4
protein and BAL cell IFN-γ and IL-4 mRNA levels was
observed [69]. To test the effect of early life antibiotic ex-
posure to the microbiota and subsequent allergic asthma
susceptibility Russell et al., treated neonatal mice with
clinical doses of Vancomycin and Streptomycin. Changes
in the resident gut microbiota and subsequent asthma
susceptibility were documented. In mice treated with
Streptomycin there was no significant effect upon the
microbiota or asthma risk. However in mice treated with
vancomycin it was noted that there was a reduction in mi-
crobial diversity and changes in bacterial population com-
position were observed leading to a heightened risk of
asthma development upon allergic challenge. As neither
antibiotic had an effect upon adult mice, one might infer
that the hygiene hypothesis is of relevance only in neo-
natal shift in microbial diversity and composition [70].
Russell et al., investigated whether or not this effect held
true for perinatal antibiotic treated mice and the risk of
developing hypersensitivity pneumonitis, a TH1–TH17
mediated lung disease. Contrary to the previous findings
severity of the disease increased dramatically with Strepto-
mycin. It was concluded that perinatal antibiotics affect
the resident gut microbiota in a highly selective manner
and this then leads to a change in susceptibility to TH2 or
TH1-TH17 driven lung inflammatory diseases [71].
The prevalence of Helicobacter pylori, which was once
the dominant bacteria in the stomach and had strong
maternal transmission, is now decreasing and with it
possibly the protective effects this bacteria seems to have
against asthma development [72]. Studies have shown
that childhood acquisition of H. pylori reduces the risk
of allergy and asthma [72]. In developing countries
nearly all adults harbour the gastric bacterium H. pylori
but in industrialised countries its prevalence is much
lower [73]. In industrialised countries such as the United
States fewer than 10% of children under 10 years of age
are colonised with H. pylori [74]. However it should be
noted that H. pylori acquisition does not appear to be
associated with adult onset asthma suggesting that the
pathogenic risk factors for adult onset asthma may differ
from those for childhood asthma [74].
It is believed that microaspiration, which occurs in
healthy individuals but has a higher prevalence in asth-
matics, could in part explain the presence of oral micro-
biota in the lower lung [15]. However this does not fully
explain why some individuals have a higher relative
abundance of certain bacteria originating from the upper
respiratory tract [15, 75].
In a recent study by Marri et al., induced sputum sam-
ples from a mild active asthmatic and non-asthmatic co-
hort of adults was examined and it was determined that
all sputum samples contained the 5 main bacterial gen-
era with Firmicutes, Proteobacteria and Actinobacteria
making up 90% of the sequence reads. It was further
shown that Proteobacteria levels were elevated in asth-
matics and Firmicutes and Actinobacteria were more
common in the non-asthmatic cohort. From this study it
was determined that mild asthma was more similar in
microbial composition to that of severe asthmatics that
to the non-asthmatic group [76].
The “disappearing microbiota” hypothesis contends
that as we become less colonised by ancient commensal
microorganisms, which aid in a multitude of processes
such as vitamin uptake and immunity, we become more
susceptible to attack by potential pathogenic microorgan-
isms. A shift in an individual’s microbial balance may have
detrimental consequences. The “disappearing microbiota”
hypothesis has been studied in relation to the increased
and decreased prevalence of several diseases in developed
nations. While the hygiene hypothesis highlights our sus-
ceptibility to infection caused by our decreased sampling
of microorganisms from the environment the disappearing
microbiota hypothesis suggests that our susceptibility is
due to a decrease in ancestral microorganisms which
offered protection [77].
Lung epithelia and mucosal immune defences
While the role of the gut microbiota in shaping the mu-
cosal immune system, the symbiosis between the gut
microbiota and intestinal mucosa, and the importance of
barrier function within the gut is well understood, there
remains a paucity of information pertaining to the lung
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[11]. As the lungs are directly exposed to the environ-
ment the epithelium is the first line of defence against
infection [78, 79]. In fact the lungs have the largest epithe-
lial surface of the body [80]. By producing inflammatory
products such as cytokines, growth factors, chemokines,
lipid mediators, peptide mediators and reactive oxygen/ni-
trogen species the respiratory epithelial cells regulate the
inflammatory response in the airways [81]. The epithelium
acts as a barrier which prevents inhaled pathogens gaining
access. Club and type II alveolar epithelial cells produce a
surfactant which effectively traps pathogens and mucocili-
ary clearance aid pathogen removal. The epithelium can
function as a catabolic barrier for proteases and peptides
with the epithelium expressing cell surface peptidases and
producing protease inhibitors. The epithelium barrier
function is further augmented by integral tight junction
proteins [81]. The cells of the innate immune response in-
clude macrophages, neutrophils and monocytes which
utilise pathogen recognition molecules (PRMs) to recog-
nise pathogen association molecular patterns (PAMPs)
leading to the production of antimicrobial products
[78, 81]. Well known cell surface receptors include
Toll-like receptors which can recognise a wide variety
of viral and bacterial PAMPs such as LPS [78, 82].
Asthma is a heterogenous disease, with airway inflam-
mation induced by epithelial exposure to allergens, pol-
lutants and microbes which further stimulate the
underlying APC (antigen presenting cells) cells inducing
an immune response [83]. This epithelial exposure can
result in a predominantly eosinophilic or neutrophilic
cell influx into the airway. The allergic subtype, which
responds to environmetal allergens, is characterised by
increased eosinophil, basophils, and mast cells along
with expansion of the T helper 2 cell (TH2 cell) subtype.
As the epithelial or mucosal barrier is where the allergen
presents itself, a breakdown in these physical barriers,
the site of allergen presentation, can further propagate
allergic, inflammatory response [8]. Indeed fungal spores,
which are potent allergens, are postulated to damage the
epithelial barrier by inducing cell shrinkage and subse-
quent inflammation and barrier breakdown [84].
The interaction of the APC with the epithelium is the
critical event in the resulting immune response. Den-
dritic cells act as sentinels, reacting to the exposure to
certain allergens and pathogens from the environment.
Dendritic cells activate an appropriate immune re-
sponse after exposure to an allergen dependent on the
appropriate mechanism of action for clearing the in-
vading pathogen. It has been noted that mice lacking in
DCs have major deficiencies in their antibacterial, anti-
viral and antifungal immunity. From recent murine
studies it is believed that the epithelium has a key role
in the activation of dendritic cells after exposure to an
adverse pathogen or allergen and that there is an
established epithelia-dendritic cell communication
pathway [85].
Alveolar macrophages are the primary microbial sam-
pling and clearance mechanism within the lung lumen and
play an integral role in pulmonary host defense positioned
at the interface between the mucosa and the external en-
vironment [86]. The composition of the microbiome in an
asthmatic lung will consequentially effect macrophage
sampling. Indeed the function of the alveolar macrophages
may also effect what microbes persist in the lung and
hence influence the resulting airway microbiome. Studies
on alveolar macrophages in smokers have demonstrated
that accumulation of tobacco smoke particulates in the
lysosome effects migration and response to Mycobacter-
ium tuberculosis [87]. These observations should also be
noted with regard to asthmatics and their lung microbiota,
as failure to effeciently clear certain species may result in
persistence and imbalance.
The Virome and asthma
Epidemiological studies across five continents spanning
three decades have revealed a strong link between re-
spiratory infections and the pathogenesis of asthma [3].
Respiratory syncytial virus (RSV), metapneumovirus,
coronavirus, parainfluenza and human rhinovirus are
just some of a plethora of human viruses which are
known to be connected with respiratory diseases like
asthma [88]. Human rhinoviruses can act as a trigger for
asthma exacerbations [81]. Viral respiratory tract infec-
tions, most commonly rhinovirus infections, can have a
serious effect on asthmatic patients or people at risk of
developing asthma, causing exacerbations and worsening
disease prognosis [88]. Some emerging evidence has
shown that individuals with asthma may have deficien-
cies in antiviral activity and a dysfunctional epithelial
barrier, increasing susceptibity to severe viral respiratory
infections with more potential for exacerbations [88].
Sigurs et al., have determined that acute RSV infections,
occurring in conjuction with a family history of asthma,
synergistically increase the risk of asthma development
in an invidual, illustrating that this gene-by-environment
interaction has prognostic implications in asthma [88, 89].
Viruses have been seen to predispose individuals to sec-
ondary bacterial infection. Upon exposure to RSV there
is an increase in the adherence of Streptococcus pneu-
moniae to human epithelial cells [81, 90]. Respiratory
virus infection markedly increases emergency room
admissions in relation to asthma exacerbations [3].
Wheezing respiratory viral illnesses from birth to
3 years of age, in high risk children (parent who tests
positive for respiratory allergies or a history of diag-
nosed asthma) increase the risk of asthma development
10 fold when the child reaches 6 years of age [91]. It
has also been shown that severe respiratory syncytial
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virus bronchiolitis in infancy, predisposes to the develop-
ment of adult asthma [92]. Respiratory virus (RV) and
RSV are capable of activating a range of proinflammatory
cytokines, chemokines, growth factors, adhesion molecules
and mucins, relevant to the pathophysiology of asthma [3].
The mycobiome and asthma
The bacterial microbiome of the lungs has been the
main focus of research to date, however the fungal
microbiome/mycobiome of the lungs warrants investiga-
tion [93]. A marker for fungal exposure, extracellular
polysaccharides, derived from Aspergillus and Penicil-
lium are now known to be inversely associated with
asthma [94]. A recent investigation of pooled sputum
samples from asthma patients and controls identified
136 fungal species of which 90 species were more com-
mon in asthmatics. Psathyrella candolleana, Malassezia
pachydermatis, Termitomyces clypeatus and Grifola sor-
dulenta were most commonly found in asthmatics and
Eremothecium sinecaudum, Systenostrema alba, Clados-
porium cladosporioides and Vanderwaltozyma polyspora
were more prevalent in the sputum samples of the con-
trol group [95]. Wheeler et al., have demonstrated that
antifungal drugs cause a fungal dysbiosis in mice and
this dysbiosis results in an increase in the severity of air-
way inflammatory diseases such as asthma [96]. It has
been well recognised for centuries that mould exposure
can lead to an exacerbation of asthma [84]. In certain
patients, mould exposure can have detrimental effect-
sleading to increased disease severity, hospital admis-
sions, and increased risk of bronchial reactivity and
death [84]. Environmental risk factors such as pollen,
animal dander and mould spores and their impact on
asthma were examined from 1985 to 1989 in a cohort of
asthmatics ranging in age from 5 to 34 years in Chicago,
US. It was discovered that there was a 2.16 times greater
chance of an asthma related death on days when the
mould spore count reached >1000 spores per cubic
meter. While factors such as genetics and the patients
socioeconomic situation have important roles, there ap-
pears to be a temporal relationship between the high en-
vironmental spore count and subsequent asthma attacks
[97]. The summer-autumn period of asthma admissions
and deaths corresponds with the peak in environmental
mould spores seen at this time [84].
It has been reported by Black et al., in 37 patients ad-
mitted to the ICU for an acute asthma attack, that 54%
tested positive in a skin test for fungal spores which in-
cluded Alternaria tenuis, Cladosporium cladosporides,
Epicoccum nigrum and Helminthosporium maydis [98].
O’ Driscoll et al., recruited 181 patients, aged between
16 and 60 years of age and divided them into three
groups; severe, moderate and mild, dependent on their
number of lifetime hospital admissions. 76% of patients
with severe asthma tested positive in a skin test toone or
more moulds including Aspergillus fumigatus, Penicillium
notatum, Cladosporium herbarum, Alternaria alternata
or the yeast Candida albicans in comparison to lower
rates of positivity in patients with moderate or mild
asthma (16–19%) [99].
Exposure to fungal allergens can have a devastating
impact onasthmatics. Fungi contain proteins which are
detrimental to the airway epithelium, enhance additional
reactions and also act as allergens [84]. It is possible that
the long term fungal colonisation of an atopic patient
may provide a chronic source of allergen exposure,
propagate airway inflammation and increase severity of
asthma phenotype [84].
Conclusion
There is an emerging consensus that the microbiome
potentially plays a critical role in disease development, in-
cluding in the pathogenesis of airway conditions such as
asthma [100]. Asthma rates are increasing and thanks to
meta-genomics techniques it is now possible to define the
composition of microbes in the lungs. It is now possible to
determine whether changes in the composition of the
lower airway microbiota influences the complex patho-
physiology of a chronic lung disease such as asthma.
Emerging studies have demonstrated that the role of the
gut and lung microbiota and the resulting immune en-
gagement cannot be ignored when studying asthma dis-
ease progression. Recent studies have demonstrated that
oral antibiotics and antimycotics alter the gut microbiota
exacerbating allergic asthma symptoms in mice. The
resulting reduction in gut microbial diversity and modifed
population composition was found to lead to increased al-
lergic symptoms. Modification of commensal microbial
species such as clostridia species have been implicated in
these observations. Indeed clostridial dervied SCFAs, such
as butyrate and actetate, are responsible for inducing mu-
cosal Treg differentation and function [63, 101]. Studies to
date suggest that a disrupted microbiota or shift in an in-
dividual’s microbial balance could possibly have detrimen-
tal effects. Further research is now required to fully dissect
this role and ultimately pave the way for the emergence of
new therapeutic strategies in combating these conditions.
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